Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection
- PMID: 16785511
- DOI: 10.4049/jimmunol.177.1.162
Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection
Abstract
The establishment of tumor escape mutants, which can be driven by innate and/or adaptive immune effector cells, presents a significant obstacle in the development of successful tumor immunotherapies. Our study documents that tumors growing within an immune-privileged site within the eye develop a tumor escape phenotype in the absence of selective T cell pressure. P815 tumor cells that are recovered from progressively growing tumors within the anterior chamber of the eye escape elimination when injected into the flanks of a second group of syngeneic DBA/2 mice that were previously immunized against P815 tumor cells. The escape phenotype of eye-derived P815 tumors was stable and permanent when the tumor cells were cultured in vitro. Eye-derived tumor cells recovered from the anterior chamber of CB-17 SCID mice also escaped elimination when injected into the flanks of immunized mice, demonstrating that selective pressure by tumor Ag-specific T cells did not contribute to the development of the escape phenotype. In vitro studies demonstrated that eye-derived tumor cells were not lysed by specific CTL and were unable to restimulate primed Ag-specific T cells. Immune escape of eye-derived tumor cells was not due to down-regulation of either MHC class I or ICAM-1. Our data demonstrate that the immune-privileged environment within the eye induces a tumor escape phenotype that is not driven by selective T cell pressure. We predict that immune escape within the eye is driven by the unique ocular environment that permanently alters gene expression in eye-derived tumor cells.
Similar articles
-
Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.Transplantation. 1991 Jul;52(1):128-33. doi: 10.1097/00007890-199107000-00026. Transplantation. 1991. PMID: 1907041
-
Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.Curr Eye Res. 2006 Jan;31(1):43-55. doi: 10.1080/02713680500477339. Curr Eye Res. 2006. PMID: 16421019
-
Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.J Immunol. 2004 Feb 1;172(3):1567-74. doi: 10.4049/jimmunol.172.3.1567. J Immunol. 2004. PMID: 14734736
-
Ocular immune privilege and CTL tolerance.Immunol Res. 2004;29(1-3):103-12. doi: 10.1385/IR:29:1-3:103. Immunol Res. 2004. PMID: 15181274 Review.
-
Influence of immune privilege on ocular tumor development.Ocul Immunol Inflamm. 2010 Apr;18(2):80-90. doi: 10.3109/09273941003669950. Ocul Immunol Inflamm. 2010. PMID: 20370332 Free PMC article. Review.
Cited by
-
Epidemiology and tumor microenvironment of ocular surface and orbital tumors on growth and malignant transformation.Front Oncol. 2024 Oct 3;14:1388156. doi: 10.3389/fonc.2024.1388156. eCollection 2024. Front Oncol. 2024. PMID: 39421442 Free PMC article. Review.
-
CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination.J Immunol. 2010 Dec 1;185(11):6706-18. doi: 10.4049/jimmunol.0903411. Epub 2010 Nov 1. J Immunol. 2010. PMID: 21041723 Free PMC article.
-
IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.J Immunol. 2011 Oct 15;187(8):4219-28. doi: 10.4049/jimmunol.1100826. Epub 2011 Sep 14. J Immunol. 2011. PMID: 21918192 Free PMC article.
-
Epigenetic regulation of CXCR4 expression by the ocular microenvironment.Invest Ophthalmol Vis Sci. 2013 Jan 9;54(1):234-43. doi: 10.1167/iovs.12-10643. Invest Ophthalmol Vis Sci. 2013. PMID: 23188729 Free PMC article.
-
Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.Cancer Res. 2013 Nov 1;73(21):6462-70. doi: 10.1158/0008-5472.CAN-11-2572. Epub 2013 Sep 26. Cancer Res. 2013. PMID: 24072749 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous